The American Society for Clinical Pharmacology & Therapeutics(ASCPT) hosted a Patient Forum on March 28 at the 2024 annual meeting. I was privileged to chair the discussion, which centered on...
Read More
The Mobilise-D Consortium gathered in Edinburgh, Scotland on March 20, 2024 for an end-of-project conference, which turned into a day of celebration of science. The idea of putting together efforts...
Read More
Koneksa contributed to the new Digital Medicine Society (DiMe) V3+ framework, which adds usability to the process of validating digital health technologies (DHTs). Usability is an important aspect of successful…
The recent Alzheimer’s and Parkinson’s Disease Conference (ADPD) demonstrated that it is an exciting time for drug development in Parkinson’s disease. Parkinson’s disease is being redefined by alpha synuclein biology,…
“Rare” diseases are something of a misnomer: about 30 million Americans, half of them children, have a rare disease – and 90% have no approved treatments at all. The need…
The balance of healthcare innovation lies in developing new treatments, while also ensuring that everyone has access and nobody is left behind. At Koneksa, our team has been busy pushing...
Read More
Koneksa recently participated in two milestone gatherings in the digital health community. Let’s talk about what they were and why they matter! The first was the first meeting of the…
Another year has flown by! We’re always looking ahead, but it’s also good to look back. In 2022, our team has grown, changed, and affected clinical research in many ways….
At the recent CNS Summit – an annual gathering of R&D life science leaders that has taken place since 2009 – Koneksa was proud to sit down with some of…
Using data from digital health technologies is making it possible to measure the performance of investigational treatments more rapidly, completely, and accurately than ever before. What’s a digital biomarker?Biomarkers are,…
